ImmunoGen initiated with a Neutral at Goldman Sachs

Goldman Sachs analyst Andrea Tan initiated coverage of ImmunoGen with a Neutral rating and $17 price target. The firm says that while Elahere uptake to date has benefited from strong physician education and adoption, robust testing, and broad payor access, it is looking to understand future drivers of growth. The analyst is also monitoring ImmunoGen’s progress with other pipeline assets, including pivekimab sunirine.